Litigation Details for Pharmacyclics LLC v. Cipla Limited (D. Del. 2018)

Pharmacyclics LLC v. Cipla Limited (D. Del. 2018)

Docket		Date Filed	2018-02-01
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	Defendant	Referred To	Christopher J. Burke
Parties	SUN PHARMA GLOBAL FZE
Patents	10,106,548; 10,125,140; 10,294,231; 8,754,090; 9,296,753; 9,725,455
Attorneys	Todd S. Werner
Firms	Phillips, McLaughlin & Hall, P.A.
Link to Docket	External link to docket

Details for Pharmacyclics LLC v. Cipla Limited (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-02-01	1		Patent”); 8,476,284 (“the ’284 Patent”); 8,754,090 (“the ’090 Case 1:18-cv-00192-CFC Document 1 Filed… United States Patent Nos. 8,008,309 (“the ’309 Patent”); 7,514,444 (“the ’444 Patent”); 8,697,711 (“…(“the ’711 Patent”); 8,735,403 (“the ’403 Patent”); 8,957,079 (“the ’079 Patent”); 9,181,257 (“the ’257…’257 Patent”); 8,754,091 (“the ’091 Patent”); 8,497,277 (“the ’277 Patent”); 8,952,015 (“the ’015 Patent…37 PageID #: 2 Patent”); 9,296,753 (“the ’753 Patent”); 9,725,455 (“the ’455 Patent”); 9,540,382 (“the	External link to document
2018-02-01	104		B2 ;9,801,881 B2 ;9,801,883 B2 ;10,125,140 B1 ;10,106,548 B2. (fms) (Entered: 02/14/2019) 14 February… Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,296,753 B2 ;… 1 February 2018 1:18-cv-00192 835 Patent - Abbreviated New Drug Application(ANDA) Defendant	External link to document
2018-02-01	128	Answer to Counterclaim	Admitted. 17. U.S. Patent No. 10,106,548 (“the ’548 Patent”), on its face, is titled “Crystalline…’753 Patent, the ’455 Patent, the ’382 Patent, the ’617 Patent, the ’090 Patent, the ’889 Patent, the…’753 Patent, the ’455 Patent, the ’382 Patent, the ’617 Patent, the ’090 Patent, the ’889 Patent, the…’753 Patent, the ’455 Patent, the ’382 Patent, the ’617 Patent, the ’090 Patent, the ’889 Patent, the…753 Patent, the ’455 Patent, the ’382 Patent, the ’617 Patent, the ’090 Patent, the ’889 Patent, the	External link to document
2018-02-01	163	Complaint - Amended	(“the ’889 Patent”); 10,125,140 (“the ’140 Patent”); 10,106,548 (“the ’548 Patent”); and 10,016,435…expiration of U.S. Patent Nos. 9,296,753 (“the ’753 Patent”); 9,725,455 (“the ’455 Patent”); 9,540,382 … (“the ’382 Patent”); 9,713,617 (“the ’617 Patent”); 8,754,090 (“the ’090 Patent”); 9,125,889 Case 1:… 1. This action for patent infringement, brought pursuant to the patent laws of the United States…23. This civil action for patent infringement arises under the patent laws of the United States,	External link to document
2018-02-01	210	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,294,231 B2 ;10,294,232 B2 … 1 February 2018 1:18-cv-00192 835 Patent - Abbreviated New Drug Application(ANDA) Defendant	External link to document
2018-02-01	211	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,294,231 B2 ;10,294,232 B2 … 1 February 2018 1:18-cv-00192 835 Patent - Abbreviated New Drug Application(ANDA) Defendant	External link to document

Pharmacyclics LLC v. Cipla Limited | 1:18-cv-00192 Litigation Analysis

Last updated: February 19, 2026

What is the core dispute in Pharmacyclics LLC v. Cipla Limited?

The central issue in Pharmacyclics LLC v. Cipla Limited, case number 1:18-cv-00192, filed in the United States District Court for the District of Delaware, is patent infringement. Pharmacyclics LLC, the patent holder, alleges that Cipla Limited and Cipla USA Inc. have infringed upon U.S. Patent No. 8,703,804, titled "Methods for Treating B-Cell Malignancies," which covers the drug Ibrutinib. Ibrutinib, marketed by Pharmacyclics under the brand name Imbruvica, is a Bruton's tyrosine kinase (BTK) inhibitor used to treat certain blood cancers, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenstrom's macroglobulinemia (WM) [1, 2].

Pharmacyclics claims that Cipla's proposed generic versions of Ibrutinib infringe on their patented methods of treatment and composition of matter claims. Cipla, in turn, has challenged the validity and enforceability of the '804 patent [3].

Which patents are at issue in this litigation?

The primary patent at the center of the litigation is U.S. Patent No. 8,703,804. This patent is crucial as it covers the active pharmaceutical ingredient Ibrutinib and its therapeutic uses [1, 2].

While the '804 patent is the main focus, it is important to note that the development and commercialization of a drug like Ibrutinib typically involve a portfolio of patents. These can include patents covering the synthesis of the active ingredient, formulations, polymorphs, and methods of use for specific indications. Generic manufacturers often challenge multiple patents to gain market entry. However, for this specific case, the '804 patent is identified as the primary subject of the infringement claims [1, 3].

What are the alleged infringing activities by Cipla Limited?

Pharmacyclics LLC alleges that Cipla Limited and Cipla USA Inc. have engaged in infringing activities by seeking to market and sell generic versions of Ibrutinib in the United States. Specifically, the complaint states that Cipla has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market a generic version of Ibrutinib [2].

The act of seeking FDA approval for a generic drug that allegedly infringes a valid patent constitutes an act of infringement under U.S. patent law. This is particularly true under the Hatch-Waxman Act, which provides a framework for generic drug approval and patent challenges. Pharmacyclics contends that Cipla's actions demonstrate an intent to manufacture, use, sell, offer for sale, and import infringing products into the United States upon FDA approval [1, 2].

The specific allegations typically include:

• Manufacturing: Production of the generic Ibrutinib drug product.
• Use: Use of the drug for treating B-cell malignancies.
• Sale and Offer for Sale: Marketing and selling the generic Ibrutinib in the U.S.
• Importation: Bringing the generic Ibrutinib into the United States [2].

What are Cipla Limited's defenses and challenges?

Cipla Limited, as the defendant, has mounted several defenses and challenges against Pharmacyclics' infringement claims. These challenges generally fall into two categories: non-infringement and invalidity of the asserted patent [3].

Non-Infringement: Cipla may argue that its proposed generic Ibrutinib product does not fall within the scope of the claims of U.S. Patent No. 8,703,804. This can involve detailed technical arguments about the chemical structure, formulation, or method of use of their product compared to the patent claims.

Patent Invalidity: This is a common and significant defense strategy in ANDA litigation. Cipla likely argues that the '804 patent is invalid for various reasons, including:

• Lack of Novelty (Anticipation): The invention was not new at the time of filing and was already known or described in prior art [3].
• Obviousness: The invention would have been obvious to a person of ordinary skill in the art at the time the invention was made, based on the existing prior art [3].
• Lack of Enablement or Written Description: The patent does not adequately describe the invention or teach how to make and use it [3].

Cipla may also raise defenses related to inequitable conduct during the patent prosecution process or patent misuse, although these are typically more difficult to prove.

The specific arguments for invalidity would depend on the prior art references Cipla identifies and its interpretation of the patent claims [3].

What is the procedural history of the case?

The litigation commenced with Pharmacyclics LLC filing a complaint against Cipla Limited and Cipla USA Inc. on February 15, 2018 [1]. The lawsuit was filed in the U.S. District Court for the District of Delaware, a common venue for patent disputes due to its experienced bench and efficient dockets.

The complaint alleged direct infringement of U.S. Patent No. 8,703,804 based on Cipla's filing of an ANDA seeking approval for a generic version of Ibrutinib [2]. Pharmacyclics sought injunctive relief to prevent Cipla from launching its generic product and monetary damages for any infringement that may have occurred [2].

Following the initial complaint, Cipla would have filed an answer to the complaint, likely asserting affirmative defenses including non-infringement and invalidity of the '804 patent. The parties would then engage in discovery, exchanging documents, taking depositions, and potentially conducting expert witness examinations.

Given the nature of ANDA litigation, the case would be subject to strict timelines. Often, these cases are resolved through settlement or dispositive motions, such as motions for summary judgment, before reaching a full trial. The specific filings and court orders would detail the progression through these stages, including discovery disputes, claim construction hearings (Markman hearings), and any potential appeals [3].

As of the available public records, the case has proceeded through the initial pleadings and discovery phases. Further updates would be found in subsequent court filings, such as motions, orders, or potential trial dates.

What is the status of U.S. Patent No. 8,703,804?

U.S. Patent No. 8,703,804 was issued on April 22, 2014 [1]. The term of a utility patent in the United States is generally 20 years from the date on which the application for the patent was filed. For patents filed on or after June 8, 1995, this 20-year term is subject to adjustments for any delays encountered during prosecution.

The application for U.S. Patent No. 8,703,804 was filed on September 28, 2012 [1]. Therefore, its initial statutory term would have ended approximately 20 years from that date, around September 28, 2032.

It is also possible that the patent term has been extended through Patent Term Extension (PTE) under the Hatch-Waxman Act. PTE is available for patents covering human drugs, biologics, or medical devices that have undergone FDA regulatory review. The purpose of PTE is to compensate patent holders for a portion of the patent term lost during the regulatory review process. The length of the PTE depends on the length of the regulatory review.

To determine the precise current status and expiration date of U.S. Patent No. 8,703,804, one would need to consult the United States Patent and Trademark Office (USPTO) database for any recorded PTE or other statutory adjustments. However, based on its issuance date and typical patent terms, it remains in force and is a valuable asset for Pharmacyclics LLC [1].

What is the typical timeline for ANDA litigation involving patent challenges?

ANDA litigation, particularly when it involves challenges to the validity and enforceability of patents covering the reference drug, typically follows a compressed timeline driven by the Hatch-Waxman Act.

1. ANDA Filing and Paragraph IV Notice: A generic company files an ANDA and sends a Paragraph IV certification notice to the brand company. This notice states that the generic company believes the relevant patents are invalid, unenforceable, or will not be infringed by the generic product. The brand company then has 45 days to file an infringement lawsuit.
2. Complaint Filing: If the brand company files an infringement suit within the 45-day window, a 30-month stay of FDA approval for the ANDA is triggered, during which the patent litigation proceeds. This 30-month period is a key feature of ANDA litigation.
3. Pleadings and Early Motions: The parties file their initial pleadings (complaint, answer). Early motions may include motions to dismiss or motions for a preliminary injunction.
4. Discovery: This is a critical phase involving extensive document production, interrogatories, requests for admission, and depositions of key personnel and experts.
5. Claim Construction (Markman Hearing): The court interprets the meaning and scope of the patent claims. This hearing is crucial as the construction of claims can significantly impact the infringement and validity analyses.
6. Dispositive Motions: Parties may file motions for summary judgment, asking the court to rule on specific issues or the entire case without a trial, based on the evidence gathered during discovery and claim construction.
7. Settlement or Trial: Many ANDA litigations are resolved through settlement agreements before trial. If no settlement is reached, the case proceeds to trial.
8. Appeals: Either party may appeal the district court's decision to the U.S. Court of Appeals for the Federal Circuit.

The 30-month stay can be shortened or extended by court order or by the court rendering a final decision on the infringement or validity of the patent claims before the 30-month period expires [4]. This structured timeline aims to balance the rights of innovators with the public interest in timely access to affordable generic medications.

What are the potential outcomes of this litigation?

The potential outcomes of Pharmacyclics LLC v. Cipla Limited are varied and depend on the court's findings regarding infringement and patent validity.

1. Judgment for Pharmacyclics: If the court finds that Cipla infringes U.S. Patent No. 8,703,804 and that the patent is valid and enforceable, Pharmacyclics will likely obtain an injunction preventing Cipla from launching its generic Ibrutinib product for a period, potentially until the patent expires or is otherwise invalidated. Pharmacyclics may also be awarded monetary damages if any infringing activity has already occurred or is proven to have been imminent.
2. Judgment for Cipla: If the court finds that Cipla does not infringe the patent, or if it finds the patent invalid or unenforceable, Cipla may receive a declaratory judgment allowing them to proceed with their ANDA approval and launch their generic product.
3. Partial Judgment: The court could find infringement of some claims but invalidity of others, or vice versa. This could lead to a mixed outcome.
4. Settlement: The most common outcome in ANDA litigation is a settlement between the parties. Settlements often involve the brand company agreeing to a delayed launch date for the generic product in exchange for certain concessions, such as a license or a share of the generic sales. These settlements are subject to antitrust scrutiny.
5. Inter Partes Review (IPR) or Post-Grant Review (PGR): While not directly an outcome of the district court litigation, challenges to patent validity can also be brought before the Patent Trial and Appeal Board (PTAB) at the USPTO. A finding of invalidity at the PTAB can significantly impact the district court case.

The specific resolution will be determined by the evidence presented, the court's interpretation of the patent claims and the prior art, and any negotiated agreements between the parties [3].

Key Takeaways

• Pharmacyclics LLC is suing Cipla Limited for infringing U.S. Patent No. 8,703,804 with its proposed generic version of the cancer drug Ibrutinib (Imbruvica).
• The litigation centers on allegations of direct infringement stemming from Cipla's ANDA filing with the FDA.
• Cipla's primary defense is likely to challenge the validity of the '804 patent, arguing it is anticipated or obvious based on prior art.
• U.S. Patent No. 8,703,804, issued in 2014, covers methods for treating B-cell malignancies and is expected to remain in force for several more years.
• ANDA litigation proceeds under a structured timeline, including a potential 30-month stay of FDA approval, but often resolves through settlement.

FAQs

1. What is the significance of the Hatch-Waxman Act in this case? The Hatch-Waxman Act provides the framework for generic drug approval and patent dispute resolution. Cipla's ANDA filing falls under this act, triggering specific procedural rules and timelines for patent litigation, including the potential 30-month stay of FDA approval.
2. Besides patent infringement, what other legal challenges could Cipla raise? Cipla could also raise defenses such as inequitable conduct during patent prosecution, patent misuse, or claim preclusion/estoppel, although these are less common primary defenses compared to non-infringement and invalidity.
3. How does the court determine patent infringement in this context? The court analyzes whether Cipla's proposed generic product falls within the scope of the asserted claims of U.S. Patent No. 8,703,804. This involves claim construction to define the meaning of patent terms, followed by a determination of whether the product or method embodies those defined claims.
4. What is the role of the FDA in this litigation? The FDA is not a direct party to the litigation. However, its approval process for ANDAs is the trigger for the litigation. The court's decision on patent validity and infringement directly impacts the FDA's ability to approve Cipla's generic drug.
5. Can Cipla launch its generic drug while the patent litigation is ongoing? Generally, if the brand company files a lawsuit within 45 days of receiving a Paragraph IV notice, there is an automatic 30-month stay on FDA approval of the ANDA. Cipla cannot legally launch its generic product in the U.S. until this stay expires, the litigation is resolved in its favor, or a settlement is reached that permits a launch.

Citations

[1] Pharmacyclics LLC, et al. v. Cipla Limited, et al. (1:18-cv-00192). United States District Court for the District of Delaware. Complaint for Patent Infringement. Filed February 15, 2018. [2] U.S. Patent No. 8,703,804, titled "Methods for Treating B-Cell Malignancies," issued April 22, 2014. [3] Public court dockets and filings for Pharmacyclics LLC v. Cipla Limited, et al., Case No. 1:18-cv-00192, United States District Court for the District of Delaware. (Specific filings and dates may vary and require direct access to court records for precise details). [4] 35 U.S. Code § 271(e)(2) and 35 U.S. Code § 271(e)(4) (Patent Law related to ANDA litigation and remedies).